Stay updated with breaking news from Ventricular Dysfunction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation
Erectile Dysfunction Devices Market has increased owing to the rising prevalence of erectile dysfunction cases among men. According to the CDC 2021, getting aged does not cause erectile dysfunction
/PRNewswire/ -- DelveInsight's Erectile Dysfunction Devices Market Insights and Forecast report provides the current and forecast Erectile Dysfunction Devices...
Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary
DUBLIN--(BUSINESS WIRE)--The "Left Ventricular Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.This pipeline guide provides comprehensive information on the therapeutics under development for Left Ven...